The metabolic syndrome influences the response to incretin-based therapies

Acta Diabetologica

Volumn 48, Issue 3, 2011, Pages 219-225

  Fadini, Gian Paolo ^a   De Kreutzenberg, Saula Vigili ^a   Gjini, Romelda ^a   Avogaro, Angelo ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

DPP IV; HbA1c; Hypertension; Phenotype

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCOSE; GROWTH HORMONE SECRETAGOGUE; HEMOGLOBIN A1C; INCRETIN; METFORMIN; SITAGLIPTIN; VILDAGLIPTIN;

ADULT; AGED; BODY MASS; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIASTOLIC BLOOD PRESSURE; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL THERAPY; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; WAIST CIRCUMFERENCE;

ADAMANTANE; AGED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NITRILES; PEPTIDES; PROGNOSIS; PYRAZINES; PYRROLIDINES; TREATMENT OUTCOME; TRIAZOLES; VENOMS;

EID: 80052382658     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-011-0296-7     Document Type: Review

References (35)

1. MA Nauck 1998 Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective Acta Diabetol 35 117 129 9840447 10.1007/s005920050116 1:CAS:528:DyaK1cXntF2lu7k%3D (Pubitemid 28505224)
2. LL Baggio DJ Drucker 2007 Biology of incretins: GLP-1 and GIP Gastroenterology 132 2131 2157 17498508 10.1053/j.gastro.2007.03.054 1:CAS:528:DC%2BD2sXmsVynsrY%3D (Pubitemid 46711096)
3. D Giugliano E Standl T Vilsbøll, et al. 2009 Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings? Acta Diabetol 46 173 181 19543848 10.1007/s00592-009-0134-3
4. Rotella CM, Pala L (2008) Time to insulin in type-2 diabetes: high hurdles or Santiago way? Acta Diabetol 45:67-74
5. RA DeFronzo T Okerson P Viswanathan, et al. 2008 Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study Curr Med Res Opin 24 2943 2952 18786299 10.1185/03007990802418851 1:CAS:528: DC%2BD1cXhsVKmt73K
6. T Vilsboll JJ Holst 2004 Incretins, insulin secretion and Type 2 diabetes mellitus Diabetologia 47 357 366 14968296 10.1007/s00125-004-1342-6 1:CAS:528:DC%2BD2cXis1Ggtrw%3D (Pubitemid 38491230)
7. Pala L, Pezzatini A, Dicembrini I et al. (2011, in pres) Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. Acta Diabetol
8. BF Hansen P Jensen E Nepper-Christensen B Skjolstrup 1998 Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport Acta Diabetol 35 101 103 9747963 10.1007/s005920050112 1:CAS:528:DyaK1cXltlKiurc%3D (Pubitemid 28403241)
9. SL Conarello Z Li J Ronan, et al. 2003 Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Proc Natl Acad Sci USA 100 6825 6830 12748388 10.1073/pnas.0631828100 1:CAS:528:DC%2BD3sXktlygtrw%3D (Pubitemid 36666664)
10. L Li G Yang Q Li, et al. 2008 Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels Diabetes Obes Metab 10 921 930 18093209 10.1111/j.1463-1326.2007.00832.x 1:CAS:528: DC%2BD1cXht1KltbfE
11. S Park SM Hong IS Ahn 2010 Exendin-4 and exercise improve hepatic glucose homeostasis by promoting insulin signaling in diabetic rats Metabolism 59 123 133 19766272 10.1016/j.metabol.2009.06.026 1:CAS:528:DC%2BD1MXhsFamsr%2FM
12. RA DeFronzo C Triplitt Y Qu, et al. 2010 Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin Diabetes Care 33 951 957 20107105 10.2337/dc09-1521 1:CAS:528:DC%2BC3cXnsFymu7w%3D
13. L Perreault CD Man DM Hunerdosse C Cobelli BC Bergman 2010 Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose Diabetes Res Clin Pract 90 87 94 20708814 10.1016/j.diabres.2010.06.012 1:CAS:528:DC%2BC3cXhtFajs77O
14. M Buysschaert V Preumont PR Oriot, et al. 2010 One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice Diabetes Metab 36 381 388 20598606 10.1016/j.diabet.2010.03.009 1:CAS:528:DC%2BC3cXhsVGnurvM
15. V Preumont MP Hermans S Brichard M Buysschaert 2010 Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity Diabetes Metab 36 293 298 20447851 10.1016/j.diabet.2010.02.001 1:CAS:528:DC%2BC3cXht1SqsrnF
16. E Bonora G Targher G Formentini, et al. 2004 The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study Diabet Med 21 52 58 14706054 10.1046/j.1464-5491.2003.01068.x 1:STN:280:DC%2BD2c%2FgvFKqsg%3D%3D (Pubitemid 38168029)
17. MA Nauck I Vardarli CF Deacon JJ Holst JJ Meier 2011 Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54 10 18 20871975 10.1007/s00125-010-1896-4 1:CAS:528: DC%2BC3cXhsFWqtLvN
18. G Assmann R Guerra G Fox, et al. 2007 Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations Am J Cardiol 99 541 548 17293200 10.1016/j.amjcard.2006.08.045 (Pubitemid 46215539)
19. R Kahn J Buse E Ferrannini M Stern 2005 The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 48 1684 1699 16079964 10.1007/s00125-005-1876-2 1:STN:280:DC%2BD2MvptF2hsg%3D%3D (Pubitemid 41317821)
20. T Erbas 2003 Metabolic syndrome Acta Diabetol 40 Suppl 2 S401 S404 14704875 10.1007/s00592-003-0126-7 (Pubitemid 37549054)
21. Q Liu L Adams A Broyde, et al. 2010 The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats Cardiovasc Diabetol 9 32 20678234 10.1186/1475-2840-9-32
22. Q Shang M Saumoy JJ Holst G Salen G Xu 2010 Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1 Am J Physiol Gastrointest Liver Physiol 298 G419 G424 20044510 10.1152/ajpgi.00362.2009 1:CAS:528:DC%2BC3cXjsFGgt7g%3D
23. CC Tseng MO Boylan LA Jarboe TB Usdin MM Wolfe 1996 Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats Am J Physiol 270 E661 E666 8928774 1:CAS:528:DyaK28Xis1emsr4%3D
24. FC Lynn N Pamir EH Ng, et al. 2001 Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats Diabetes 50 1004 1011 11334402 10.2337/diabetes.50.5.1004 1:CAS:528: DC%2BD3MXkvFSgur8%3D (Pubitemid 32374530)
25. G Firneisz T Varga G Lengyel, et al. 2010 Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker PLoS One 5 e12226 20805868 10.1371/journal.pone. 0012226
26. RD Carr MO Larsen K Jelic, et al. 2010 Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men J Clin Endocrinol Metab 95 872 878 20008019 10.1210/jc.2009-2054 1:CAS:528:DC%2BC3cXitVaisbc%3D
27. T Reinehr CL Roth PJ Enriori K Masur 2010 Changes of dipeptidyl peptidase IV (DPP-IV) in obese children with weight loss: relationships to peptide YY, pancreatic peptide, and insulin sensitivity J Pediatr Endocrinol Metab 23 101 108 20432813 10.1515/JPEM.2010.23.1-2.101 1:CAS:528:DC%2BC3cXlslyitLk%3D
28. Turcot V, Bouchard L, Faucher G et al. (2010) DPP4 Gene DNA Methylation in the omentum is associated with its gene expression and plasma lipid profile in severe obesity. Obesity (Silver Spring) 19:388-395
29. EK Jackson JH Dubinion Z Mi 2008 Effects of dipeptidyl peptidase IV inhibition on arterial blood pressure Clin Exp Pharmacol Physiol 35 29 34 18047624 10.1111/j.1440-1681.2007.04737.x 1:CAS:528:DC%2BD1cXotVag (Pubitemid 350197677)
30. A Marney S Kunchakarra L Byrne NJ Brown 2010 Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans Hypertension 56 728 733 20679179 10.1161/HYPERTENSIONAHA. 110.156554 1:CAS:528:DC%2BC3cXhtFKls7nL
31. EK Jackson 2010 Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome Hypertension 56 581 583 20679176 10.1161/HYPERTENSIONAHA.110. 158527 1:CAS:528:DC%2BC3cXhtFKls7vK
32. EA Gale SD Beattie J Hu V Koivisto MH Tan 2007 Recruitment to a clinical trial improves glycemic control in patients with diabetes Diabetes Care 30 2989 2992 17804681 10.2337/dc07-0155 (Pubitemid 350255230)
33. RE Amori J Lau AG Pittas 2007 Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis Jama 298 194 206 17622601 10.1001/jama.298.2.194 1:CAS:528:DC%2BD2sXnslSjuro%3D (Pubitemid 47057766)
34. DR Matthews S Dejager B Ahren, et al. 2010 Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study Diabetes Obes Metab 12 780 789 20649630 10.1111/j.1463-1326.2010.01233.x 1:CAS:528: DC%2BC3cXhtFGntbnP
35. MB Toft-Nielsen S Madsbad JJ Holst 2001 Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes J Clin Endocrinol Metab 86 3853 3860 11502823 10.1210/jc.86.8.3853 1:CAS:528:DC%2BD3MXlvFeku70%3D (Pubitemid 32755988)